UOC
RARE icon

UBS O'Connor’s Ultragenyx Pharmaceutical RARE Stock Holding History

UBS O'Connor’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-60,000
Closed -$238K – 414
2025
Q2 		$238K Buy
+60,000
New +$2.16M 0.01% 290
2024
Q4 		– Sell
-25,000
Closed -$20K – 548
2024
Q3 		$20K Sell
25,000
-15,000
-38% -$764K ﹤0.01% 449
2024
Q2 		$37K Buy
40,000
+29,300
+274% +$1.25M ﹤0.01% 460
2024
Q1 		$61K Buy
10,700
+700
+7% +$33K ﹤0.01% 436
2023
Q4 		$1.25K Sell
10,000
-85,000
-89% -$3.3M ﹤0.01% 496
2023
Q3 		$109K Buy
95,000
+85,000
+850% +$3.37M ﹤0.01% 466
2023
Q2 		$21.3K Buy
+10,000
New +$464K ﹤0.01% 530

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return